Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Myalgia 1Arthralgia 1

Interventions

Gemcitabine 6Carboplatin 3valrubicin 2Cisplatin 2vinflunine 1toripalimab 1pertuzumab 1disitamab vedotin 1cabazitaxel 1apaziquone 1XRP6258 1Watchful Waiting 1Vinblastine 1Trastuzumab 1Transurethral Resection of Bladder 1Tranexamic Acid 1Saline Solution 1RC48 antibody 1Oncolytic Virotherapy 1Mitomycin 1Methotrexate 1Magnetic Resonance Spectroscopy 1Lapatinib 1Interferons 1Interferon-alpha 1Gabapentin 1Circulating Tumor DNA 1Celecoxib 1BCG Vaccine 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Urinary Bladder Neoplasms × Gabapentin × Clear all
NCT02355886 2019-06-04

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

University of Washington

Phase 2/3 Completed
25 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡